Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Dec;60(6):911–918. doi: 10.1038/bjc.1989.389

West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes.

J M Morrison 1, A Howell 1, K A Kelly 1, R J Grieve 1, I J Monypenny 1, R A Walker 1, J A Waterhouse 1
PMCID: PMC2247250  PMID: 2690913

Abstract

The aim of this study was to test the effectiveness of a regimen of combination chemotherapy known to be active in advanced breast cancer when given as an adjuvant treatment after mastectomy. A total of 569 patients with cancer of the breast and involvement of axillary lymph nodes were randomised, after simple mastectomy with axillary sampling, to receive either no adjuvant treatment or intravenous adriamycin 50 mg, vincristine 1 mg, cyclophosphamide 250 mg, methotrexate 150 mg and fluorouracil 250 mg (AVCMF) every 21 days for eight cycles. Randomisation was stratified according to menopausal status and tumour size. Treatment was started within 14 days of surgery in 94% of patients. Eighty-eight per cent of patients received at least seven cycles of chemotherapy with no dose reduction. The median relapse-free survival was prolonged by 14 months in patients treated with AVCMF (chi2 1 = 11.7; P = 0.0006). In the premenopausal group this period was 17 months (chi2 1 = 8.8; P = 0.003) compared with 8 months in the post-menopausal group (chi2 1 = 3.3; P = 0.07). Neither overall survival nor survival in these subgroups was significantly influenced by treatment.

Full text

PDF
918

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beex L. V., Mackenzie M. A., Raemaekers J. M., Smals A. G., Benraad T. J., Kloppenborg P. W. Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour. Eur J Cancer Clin Oncol. 1988 Apr;24(4):719–721. doi: 10.1016/0277-5379(88)90304-5. [DOI] [PubMed] [Google Scholar]
  3. Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L., Brambilla C., De Lena M., Tancini G., Bajetta E., Musumeci R. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976 Feb 19;294(8):405–410. doi: 10.1056/NEJM197602192940801. [DOI] [PubMed] [Google Scholar]
  4. Brincker H., Rose C., Rank F., Mouridsen H. T., Jakobsen A., Dombernowsky P., Panduro J., Andersen K. W. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol. 1987 Nov;5(11):1771–1778. doi: 10.1200/JCO.1987.5.11.1771. [DOI] [PubMed] [Google Scholar]
  5. Elston C. W., Gresham G. A., Rao G. S., Zebro T., Haybittle J. L., Houghton J., Kearney G. The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects. Br J Cancer. 1982 May;45(5):655–669. doi: 10.1038/bjc.1982.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fisher B., Fisher E. R., Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986 Jun;4(6):929–941. doi: 10.1200/JCO.1986.4.6.929. [DOI] [PubMed] [Google Scholar]
  7. Forrest A. P., Roberts M. M., Cant E., Shivas A. Simple mastectomy and pectoral node biopsy. Br J Surg. 1976 Aug;63(8):569–575. doi: 10.1002/bjs.1800630802. [DOI] [PubMed] [Google Scholar]
  8. Howell A., Bush H., George W. D., Howat J. M., Crowther D., Sellwood R. A., Rubens R. D., Hayward J. L., Bulbrook R. D., Fentiman I. S. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet. 1984 Aug 11;2(8398):307–311. doi: 10.1016/s0140-6736(84)92684-9. [DOI] [PubMed] [Google Scholar]
  9. McGuire W. L., DeLaGarza M. Improved sensitivity in the measurement of estrogen receptor in human breast cancer. J Clin Endocrinol Metab. 1973 Dec;37(6):986–989. doi: 10.1210/jcem-37-6-986. [DOI] [PubMed] [Google Scholar]
  10. Nissen-Meyer R., Kjellgren K., Malmio K., Månsson B., Norin T. Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer. 1978 Jun;41(6):2088–2098. doi: 10.1002/1097-0142(197806)41:6<2088::aid-cncr2820410604>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  11. Padmanabhan N., Howell A., Rubens R. D. Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet. 1986 Aug 23;2(8504):411–414. doi: 10.1016/s0140-6736(86)92131-8. [DOI] [PubMed] [Google Scholar]
  12. Price L. A., Hill B. T., Marks P., Howell A., Monypenny I., Morrison J. M. Twenty-four hour combination chemotherapy: a feasibility study with implications for improved adjuvant treatment of breast cancer. Eur J Cancer Clin Oncol. 1983 Jan;19(1):1–4. doi: 10.1016/0277-5379(83)90388-7. [DOI] [PubMed] [Google Scholar]
  13. Skipper H. E. Adjuvant chemotherapy. Cancer. 1978 Mar;41(3):936–940. doi: 10.1002/1097-0142(197803)41:3<936::aid-cncr2820410322>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  14. Tormey C. Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial. Recent Results Cancer Res. 1984;96:155–165. doi: 10.1007/978-3-642-82357-2_19. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES